World's largest public-private antibiotic fund unveils first investments

The AMR Action Fund, established in the summer of 2020 by an extensive consortium of some of the world’s leading pharmaceutical companies including Novo Nordisk, is ready to announce its first two investments in the first against antimicrobial resistance (AMR).

Photo: Daniel Karmann/AP/Ritzau Scanpix

Around two years after the AMR Action Fund came into existence with the goal of aiding the development of new antibiotic drugs, the fund has announced its first two investments, a press release reports.

The firms Adaptive Phage Therapeutics (APT) and Venatorx Pharmaceuticals are set to receive undisclosed sums from the fund, which stated its goal to invest USD 1bn in smaller biotech companies when it first set out to fight antimicrobial resistance (AMR) in 2020.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs